Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PTIX 
Protagenic Therapeutics (PTIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: PTIX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.02% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.51M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta 0.38 | 52 Weeks Range 2.25 - 15.26 | Updated Date 09/17/2025 |
52 Weeks Range 2.25 - 15.26 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.13 |
Earnings Date
Report Date 2025-08-29 | When - | Estimate - | Actual -1.3664 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -189.6% | Return on Equity (TTM) -512.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1657964 | Price to Sales(TTM) - |
Enterprise Value 1657964 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.64 | Shares Outstanding 1914940 | Shares Floating 491613 |
Shares Outstanding 1914940 | Shares Floating 491613 | ||
Percent Insiders 11.21 | Percent Institutions 10.11 |
Upturn AI SWOT
Protagenic Therapeutics
Company Overview
History and Background
Information on Protagenic Therapeutics is limited as it appears to be a relatively new or private company with limited public information available. Details on its founding year and historical milestones are scarce.
Core Business Areas
- Therapeutics Development: Focuses on developing novel therapeutic agents, potentially utilizing proprietary technologies or platforms. The specific therapeutic areas of focus are currently unavailable.
Leadership and Structure
Details about the leadership team and organizational structure are not readily available in the public domain.
Top Products and Market Share
Key Offerings
- PT001: Potentially a lead drug candidate, assuming it exists, likely still in preclinical or early clinical development. Market share data is unavailable as it's unlikely to have reached commercialization. Competitors would depend on the specific therapeutic area of PT001.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated, characterized by high research and development costs, lengthy clinical trial processes, and stringent regulatory requirements.
Positioning
Given the lack of information, Protagenic Therapeutics's positioning is unknown. They would be a small player relative to large pharmaceutical companies.
Total Addressable Market (TAM)
TAM depends on the specific therapeutic area they are targeting. Without information on the target indications, the TAM cannot be determined. Positioning is likely to be a small player trying to establish itself in a niche market.
Upturn SWOT Analysis
Strengths
- Potentially innovative technology or therapeutic approach
- Strong intellectual property (if any)
- Dedicated research team (assumed)
Weaknesses
- Limited funding and resources
- Lack of clinical trial data
- Dependence on key personnel
- No commercialized products
Opportunities
- Partnerships with larger pharmaceutical companies
- Successful clinical trial results
- FDA approval of a therapeutic candidate
- Expansion into new therapeutic areas
Threats
- Failure of clinical trials
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Lack of funding
Competitors and Market Share
Key Competitors
Competitive Landscape
Impossible to evaluate without knowing their therapeutic focus and stage of development. Highly disadvantaged compared to established companies.
Growth Trajectory and Initiatives
Historical Growth: No data available.
Future Projections: No data available.
Recent Initiatives: No publicly available information on recent strategic initiatives.
Summary
Protagenic Therapeutics is likely an early-stage company with significant challenges ahead. Its success depends on its ability to secure funding, advance its therapeutic candidates through clinical trials, and compete with larger pharmaceutical companies. The company's long-term viability is uncertain given the limited information available.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Limited publicly available information; data gaps filled based on typical biotech company profiles.
Disclaimers:
This analysis is based on limited information and contains assumptions. It is not investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protagenic Therapeutics
Exchange NASDAQ | Headquaters Santa Barbara, CA, United States | ||
IPO Launch date 2016-01-05 | President, CEO & Director Mr. Barrett Evans | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://phytanix.com |
Full time employees - | Website https://phytanix.com | ||
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.